Compare Dover Corp (DOV) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dover Corp vs Regeneron Pharmaceuticals Inc — how do they compare? Dover Corp trades at $190.16 (market cap $25.45B), while Regeneron Pharmaceuticals Inc trades at $740 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 3× Dover Corp's market cap, and Dover Corp pays the higher dividend (1.11%). Which is the better fit depends on your goals — on Pluang, investors hold Dover Corp for 73 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| DOV | REGN | |
|---|---|---|
Market Cap | $25.45B | $76.14B |
Volume | 661,758 | 500,239 |
Sector | Industrials | Health |
52-Week High | $233.31 | $852.03 |
52-Week Low | $161.16 | $557.73 |
Typical Hold Time | 73 Days | 107 Days |
Enterprise Value | $26.95B | $70.85B |
Dividend Yield | 1.11% | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dover Corporation (DOV) trades at $188.29, down 1.87% on the day, with a bearish technical signal from moving averages. The company maintains strong profitability with a 13.48% net income margin and has beaten earnings expectations for three consecutive quarters. Recent acquisitions and product launches demonstrate ongoing business development. Analyst consensus remains strongly bullish with a $243.20 price target representing 29% upside potential.
The stock offers attractive upside based on analyst targets and consistent earnings performance, though technical indicators suggest near-term pressure. Key risks include market volatility and integration challenges from recent acquisitions. The company's Dividend King status and strong cash flow generation provide stability for long-term investors.
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
